Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study.

Front Cardiovasc Med · 2026 · PMC13318860 · PMID 42389639

Europe PMC DOI

hedged sentence

0.0050

closest p · 0.1× alpha

0.0050

boldest claim

The sentences

highly significantP = 0.005actually significant

Kaplan–Meier survival analysis revealed a highly significant divergence in event-free survival favoring the SGLT2i group (Log-rank P = 0.005) ( Figure 3 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.